BioSpace News Archive

Zimmer Biomet Holdings, Inc. today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 9:30 a.m. ET (6:30 a.m. PT ).

Relmada Therapeutics, Inc. today announced the dosing of the first patient in the Relight (study 304) Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of Major Depressive Disorder (MDD).

With around 90% of drugs failing to make it to market, the potential for improving efficiency within the drug development industry is clear.

Bristol Myers Squibb published its 2022 Environmental, Social, and Governance Report, which details the Company’s goals, strategies, and performance across its four ESG focus areas including ethics, integrity, and quality; health equity and access to healthcare; global inclusion and diversity; and environmental sustainability.

Medigene AG announces the expansion of the IP license for its PD1-41BB and CD40L-CD28 costimulatory switch proteins, enabling their application to additional cell types and for use in Chimeric Antigen Receptor T cell therapies.

Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, announced that the management team will participate in two upcoming investor conferences in New York, NY.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Stage 1 data analysis is complete for its Phase I/II topical clinical trial of RECCE® 327 (R327) for the treatment of patients with burn wound infections.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the dosing of the first subject in its First-in-Human Phase 0 clinical trial.

Baudax Bio, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 5, 2023.

Lynk Pharmaceuticals Co., Ltd. (referred to as “Lynk Pharmaceuticals”), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of ankylosing spondylitis (AS).